EUVIMEDEUVIMED entdecken
Open Access

Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States

Tania Kapoor iD, Lilly Murray iD, Maria Kuvaldina iD, Caroline S Jiang iD, Avery A Peace iD, Marianna Agudelo iD, Andrea Jurado iD, Davide F Robbiani iD, Oliver Klemens, Erik Lattwein, Maite Sabalza, Brian A Fallon iD und 1 weitere

Vector-Borne and Zoonotic Diseases · 2024

DOI: 10.1089/vbz.2022.0030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vector-Borne and Zoonotic Diseases, 2024. Verfasst von Tania Kapoor und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA. Hauptthemen laut MEDLINE: Encephalitis Viruses, Tick-Borne, Encephalitis, Tick-Borne, Lyme Disease, Ixodes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lyme disease (LD) affects ∼476,000 people each year in the United States. Symptoms are variable and include rash and flu-like symptoms. Reasons for the wide variation in disease outcomes are unknown. Powassan virus (POWV) is a tick-borne flavivirus that causes disease ranging from asymptomatic infection to encephalitis, neurologic damage, and death. POWV and LD geographic case distributions overlap, with Ixodes species ticks as the common vectors. Clinical ramifications of coinfection or sequential infection are unknown.

Objectives

This study's primary objective was to determine the prevalence of POWV-reactive antibodies in sera samples collected from previously studied cohorts of individuals with self-reported LD history residing in the Northeastern United States. As a secondary objective, we studied clinical differences between people with self-reported LD history and low versus high POWV antibody levels.

Methods

We used an enzyme-linked immunosorbent assay (ELISA) to quantify IgG directed at the POWV envelope (E) protein domain III in 538 samples from individuals with self-reported LD history and 16 community controls. The samples were also tested with an ELISA assay to quantify IgG directed at the POWV NS1 protein.

Results

The percentage of individuals with LD history and possible evidence of POWV exposure varied depending on the assay utilized. We found no significant difference in clinical symptoms between those with low or high POWV IgG levels in the in-house assay. Congruence of the EDIII and NS1 assays was low with only 12% of those positive in the in-house EDIII ELISA testing positive in the POWV NS1 ELISA.

Conclusions

The results highlight the difficulty in flavivirus diagnostic testing, particularly in the retrospective detection of flavivirus exposure. The findings suggest that a prospective study with symptomatic patients using approved clinical testing is necessary to address the incidence and clinical implications of LD and POWV co-infection or sequential infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalitis Viruses, Tick-BorneEncephalitis, Tick-BorneLyme DiseaseIxodesAnimalsHumansUnited StatesPrevalenceRetrospective StudiesProspective StudiesNew EnglandAntibodies, ViralImmunoglobulin G

Stichwörter der Autor:innen

Borrelia burgdorferiIxodes scapularisLyme diseasePowassan virusencephalitistick-borne flavivirus

Substanzen

Antibodies, ViralImmunoglobulin G

Autor:innen und Institutionen

  • Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
  • Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York, USA.
  • Department of Hospital Biostatistics, The Rockefeller University, New York, New York, USA.
  • Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
  • Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany.
  • EUROIMMUN US, Mountain Lakes, New Jersey, USA.

ORCID-Profile: Tania Kapoor, Lilly Murray, Maria Kuvaldina, Caroline S Jiang, Avery A Peace, Marianna Agudelo, Andrea Jurado, Davide F Robbiani, Brian A Fallon, Margaret R MacDonald

Zitieren

APA

Kapoor, T., Murray, L., Kuvaldina, M., Jiang, C. S., Peace, A. A., Agudelo, M., Jurado, A., Robbiani, D. F., Klemens, O., Lattwein, E., Sabalza, M., Fallon, B. A., & MacDonald, M. R. (2024). Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States. Vector-Borne and Zoonotic Diseases. https://doi.org/10.1089/vbz.2022.0030

Vancouver

Kapoor T, Murray L, Kuvaldina M, Jiang CS, Peace AA, Agudelo M, et al. Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States. Vector-Borne and Zoonotic Diseases. 2024. doi:10.1089/vbz.2022.0030

BibTeX
@article{Kapoor2024,
  author = {Kapoor, Tania and Murray, Lilly and Kuvaldina, Maria and Jiang, Caroline S and Peace, Avery A and Agudelo, Marianna and Jurado, Andrea and Robbiani, Davide F and Klemens, Oliver and Lattwein, Erik and Sabalza, Maite and Fallon, Brian A and MacDonald, Margaret R},
  title = {Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States},
  journal = {Vector-Borne and Zoonotic Diseases},
  year = {2024},
  doi = {10.1089/vbz.2022.0030}
}
Kostenlos starten →